Literature DB >> 2094597

Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75.

D F Clyde1.   

Abstract

The immunogenicity in adult male volunteers of sporozoites of Plasmodium falciparum and P. vivax was evaluated at the University of Maryland from 1971 to 1975. Inoculation of large numbers of sporozoites by mosquitos that had been X-irradiated proved safe and well tolerated, and the sporozoites were rendered noninfective. Three volunteers were protectively immunized by this method, one against P. falciparum, one against P. vivax, and one against both species. Protection was species- and stage-specific, but effective against all strains tested within a species, and was reflected by a rise in titre of antibody to the circumsporozoite protein.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2094597      PMCID: PMC2393030     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  6 in total

1.  Plasmodium vivax: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man.

Authors:  V C McCarthy; D F Clyde
Journal:  Exp Parasitol       Date:  1977-02       Impact factor: 2.011

2.  Specificity of protection of man immunized against sporozoite-induced falciparum malaria.

Authors:  D F Clyde; V C McCarthy; R M Miller; R B Hornick
Journal:  Am J Med Sci       Date:  1973-12       Impact factor: 2.378

3.  Immunization of man against sporozite-induced falciparum malaria.

Authors:  D F Clyde; H Most; V C McCarthy; J P Vanderberg
Journal:  Am J Med Sci       Date:  1973-09       Impact factor: 2.378

4.  Specificity of protective immunity produced by x-irradiated Plasmodium berghei sporozoites.

Authors:  R S Nussenzweig; J P Vanderberg; H Most; C Orton
Journal:  Nature       Date:  1969-05-03       Impact factor: 49.962

5.  Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. V. In vitro effects of immune serum on sporozoites.

Authors:  J Vanderberg; R Nussenzweig; H Most
Journal:  Mil Med       Date:  1969-09       Impact factor: 1.437

6.  Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites.

Authors:  D F Clyde
Journal:  Am J Trop Med Hyg       Date:  1975-05       Impact factor: 2.345

  6 in total
  33 in total

Review 1.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

2.  Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.

Authors:  Myriam Arévalo-Herrera; Liliana Soto; Blanca Liliana Perlaza; Nora Céspedes; Omaira Vera; Ana Milena Lenis; Anilza Bonelo; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

Review 3.  Advances and challenges in malaria vaccine development.

Authors:  Peter D Crompton; Susan K Pierce; Louis H Miller
Journal:  J Clin Invest       Date:  2010-12-01       Impact factor: 14.808

4.  Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin.

Authors:  Daniel Carapau; Robert Mitchell; Adéla Nacer; Alan Shaw; Caroline Othoro; Ute Frevert; Elizabeth Nardin
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

5.  Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii.

Authors:  Gloria González-Aseguinolaza; Yurie Nakaya; Alberto Molano; Edward Dy; Mariano Esteban; Dolores Rodríguez; Juan Ramón Rodríguez; Peter Palese; Adolfo García-Sastre; Ruth S Nussenzweig
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

6.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

7.  Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria.

Authors:  Nathan W Schmidt; Rebecca L Podyminogin; Noah S Butler; Vladimir P Badovinac; Brad J Tucker; Keith S Bahjat; Peter Lauer; Arturo Reyes-Sandoval; Claire L Hutchings; Anne C Moore; Sarah C Gilbert; Adrian V Hill; Lyric C Bartholomay; John T Harty
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-09       Impact factor: 11.205

8.  Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.

Authors:  Caroline Othoro; Dean Johnston; Rebecca Lee; Jonathan Soverow; Jean-Claude Bystryn; Elizabeth Nardin
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

9.  Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity.

Authors:  Else M Bijker; Guido J H Bastiaens; Anne C Teirlinck; Geert-Jan van Gemert; Wouter Graumans; Marga van de Vegte-Bolmer; Rianne Siebelink-Stoter; Theo Arens; Karina Teelen; Wiebke Nahrendorf; Edmond J Remarque; Will Roeffen; Annemieke Jansens; Dunja Zimmerman; Martijn Vos; Ben C L van Schaijk; Jorien Wiersma; André J A M van der Ven; Quirijn de Mast; Lisette van Lieshout; Jaco J Verweij; Cornelus C Hermsen; Anja Scholzen; Robert W Sauerwein
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-18       Impact factor: 11.205

Review 10.  Plasmodium vivax: who cares?

Authors:  Mary R Galinski; John W Barnwell
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.